Adding Uptravi (selexipag) to standard-of-care therapy within six months of starting treatment may reduce the risk of hospitalization and…
Articles by Marisa Wexler, MS
Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t…
The Pulmonary Hypertension Association (PHA) is fundraising and advocating with a campaign called “Let Your Light Shine” this November…
Researchers at Monash University in Australia will use newly granted funding to advance their work on a project that aims…
An upcoming clinical trial will test whether empagliflozin, a drug widely approved to treat diabetes and heart failure, might…
For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with…
The U.S. Food and Drug Administration has given Tectonic Therapeutic the go-ahead to start a Phase 2 clinical…
A committee of the European Medicines Agency (EMA) has recommended that Yuvanci, a tablet containing macitentan and tadalafil, be approved…
Tempus AI and United Therapeutics are teaming up for a study to advance the use of artificial intelligence…
The amount of normal-looking lung tissue visible on CT scans of the chest can help to predict survival outcomes and…
Chronic alcohol consumption damages the heart and blood vessels in ways that seem to set the stage for pulmonary…
A noninvasive intervention that makes use of ultrasound to target the splenic nerve — a nerve in the spleen, an…